Yes, but only indirectly. The familial early-onset panel that tests PSEN1, APP, and PSEN2 rarely applies to someone over 65, while a related genetic test — APOE genotyping — can directly shape treatment decisions at that age. These two tests get confused constantly, and the confusion matters because one changes almost nothing for an older adult while the other can determine whether a drug is offered and how closely it's monitored.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Why the Familial Panel Usually Doesn't Apply After 65
- What APOE Testing Actually Tells You
- How APOE Status Affects Lecanemab (Leqembi) Decisions
- Direct-to-Consumer Results and the Counseling Gap
- What to Do With These Results in Practice
Why the Familial Panel Usually Doesn't Apply After 65
The familial Alzheimer's panel looks for autosomal-dominant mutations that cause early-onset disease, typically before age 65. PSEN1 mutations account for roughly 30-70% of these early-onset familial cases, APP for 10-15%, and PSEN2 for about 5%, according to ARUP Laboratories' test fact sheet. Between 20% and 40% of early-onset familial cases have no identified cause even after testing.
Early-onset Alzheimer's itself makes up only about 2-10% of all Alzheimer's cases, so the panel is built for a narrow, younger population, according to Prevention Genetics' test information. For the typical late-onset dementia diagnosed in people over 65, the relevant genetic factor is a different gene entirely: APOE. Even within its intended population, the panel has limits. ARUP reports that it identifies a causative variant in about 60-80% of true early-onset familial cases, and a negative result doesn't rule out an inherited cause — the test can miss deep intronic variants and certain deletions or duplications, per ARUP's fact sheet.
What APOE Testing Actually Tells You
APOE is a gene involved in cholesterol transport, and one of its variants, APOE ε4, raises Alzheimer's risk without causing the disease outright. Carrying at least one ε4 allele increases risk by 1.2 to 3 times depending on ethnicity, according to a payer clinical policy summary from Excellus/Univera. That's a probability shift, not a diagnosis — many ε4 carriers never develop dementia, and many people without it do.
This distinction matters for how a result should be used. A positive APOE result doesn't confirm Alzheimer's and shouldn't be treated as one. Its real value for adults over 65 lies in a specific clinical decision: whether to start an anti-amyloid drug.
How APOE Status Affects Lecanemab (Leqembi) Decisions
The Alzheimer's Association's 2023 Appropriate Use Recommendations call for APOE genotyping before starting lecanemab (brand name Leqembi), because ε4 carriers — especially those with two copies of the allele — face a much higher risk of ARIA, a side effect involving brain swelling or bleeding, according to the Alzheimer's Association's lecanemab toolkit. The numbers behind that caution are specific. Published data show symptomatic ARIA-E (the swelling form) in 9% of ε4 homozygotes (people with two copies of the risk allele) compared with 2% of heterozygotes (one copy) on lecanemab.
Rates of any ARIA, including cases without symptoms, reach 45% in homozygotes versus 19% in heterozygotes, according to an NCBI Medical Genetics Summary. Because of this gap, the formal Appropriate Use Recommendations advise caution about offering lecanemab to ε4/ε4 homozygotes at all, given their elevated ARIA risk. Treatment also requires confirmed amyloid-positive status through PET or spinal fluid testing before APOE results factor into the decision, according to the recommendations published in the Journal of Prevention of Alzheimer's Disease. In practice, this means APOE results shift two things: whether a patient is a reasonable candidate at all, and how closely they're monitored for side effects during the first year of treatment if they proceed.
Direct-to-Consumer Results and the Counseling Gap
APOE results are also available outside a clinical setting. 23andMe's Genetic Health Risk Report has offered FDA-authorized APOE results since 2017, often without a genetic counselor involved, which clinical commentators flag as a problem because interpreting risk magnitude and its implications for drug eligibility is complex, according to the Excellus/Univera policy document.
Someone who orders a direct-to-consumer kit and gets an ε4/ε4 result has no built-in mechanism to connect that number to a treatment conversation. Genetic counseling before and after any familial Alzheimer's testing is recommended for this reason, typically costing around $300 (with a range of $0 to $1,000) and taking about three weeks to return results, according to a University of Wisconsin Alzheimer's Disease Research Center presentation cited in the ADRC's genetic counseling materials. A counselor can walk through what a result does and doesn't mean before it gets used to make a care decision.
What to Do With These Results in Practice
For a person over 65 considering genetic testing in the context of dementia care, the two tests serve different purposes: The practical takeaway: for most adults over 65, genetic testing only changes care decisions when it's APOE status feeding into an anti-amyloid treatment evaluation — not the familial panel designed for a younger, genetically distinct population.
- A familial panel (PSEN1/APP/PSEN2) is built for early-onset cases and will not change routine care decisions for typical late-onset dementia, per ARUP's panel documentation.
- APOE genotyping is the test that matters for anti-amyloid drug eligibility counseling and monitoring intensity, per the Alzheimer's Association's lecanemab recommendations.
- A positive APOE result should prompt a conversation about ARIA monitoring, not a dementia diagnosis on its own.
- Confirmed amyloid status via PET or cerebrospinal fluid testing is required alongside APOE results before any anti-amyloid treatment decision is finalized.
- A result obtained through a direct-to-consumer kit benefits from review with a genetic counselor before it factors into any treatment discussion with a physician.
